← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Onl Therapeutics, Inc.
Ann Arbor, MI
$4,448,408
Total funding
4
Grants
Funding over time
peak $1.4M · FY2012–22$2M$1.5M$1M$500K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$4,448,408 · 4
By mechanism
R44$1,408,246 · 1
R42$1,399,056 · 1
SB1$1,219,466 · 1
R43$421,640 · 1
Investigators at Onl Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
All-Time
Most funded here, all years
Largest grants
Preclinical development of ONL-101 for photoreceptor protection in retinal detach$1,372,371
R44 · FY2014 · EY
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$618,183
R42 · FY2020 · EY
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$499,844
SB1 · FY2018 · EY
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$499,761
SB1 · FY2017 · EY
Prevention of photoreceptor cell death with intravitreal Fas-receptor antagonist$421,640
R43 · FY2012 · EY
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$352,130
R42 · FY2021 · EY
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$300,202
R42 · FY2018 · EY
De-risking ONL1204 to enable venture capital investment for first-in-human clinical trials$219,861
SB1 · FY2018 · EY
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$120,000
R42 · FY2022 · EY
Preclinical development of ONL-101 for photoreceptor protection in retinal detach$30,875
R44 · FY2015 · EY
Therapeutic inhibition of Fas-mediated retinal cell death and inflammation in dry AMD$8,541
R42 · FY2021 · EY
Preclinical development of ONL-101 for photoreceptor protection in retinal detach$5,000
R44 · FY2015 · EY